Your browser doesn't support javascript.
loading
Effectiveness at 24 Months of Single-Source Generic Carbamazepine, Lamotrigine, or Levetiracetam in Newly Diagnosed Focal Epilepsy.
Gurbani, Suresh; Chayasirisobhon, Sirichai; Gurbani, Aditya; Tovar, Stephanie; Pietzsch, Erika; Spurgeon, Benjamin.
Afiliación
  • Gurbani S; Kaiser Permanente, Oakland, CA.
  • Chayasirisobhon S; Kaiser Permanente, Oakland, CA.
  • Gurbani A; University of Southern California, Los Angeles, CA.
  • Tovar S; Kaiser Permanente, Oakland, CA.
  • Pietzsch E; Kaiser Permanente, Oakland, CA.
  • Spurgeon B; Kaiser Permanente, Oakland, CA.
Perm J ; 25: 1-3, 2020 12.
Article en En | MEDLINE | ID: mdl-33635777
BACKGROUND: Kaiser Permanente advocates using single-source generics for brand-name drugs. We compared the effectiveness of 3 different-generation generic antiepileptic drugs (AEDs) in patients with focal epilepsies. OBJECTIVE: To compare the effectiveness of the 3 most commonly used AEDs (carbamazepine [CBZ], lamotrigine [LTG], and levetiracetam [LEV]) after 24-month monotherapy. METHODS: This is a retrospective data analysis of 646 consecutive AED-naive patients aged 1-88 years treated with CBZ, LTG, or LEV between 2006 and 2012 with dosing adjustments permitted during the first 6 months. Chi-squared test with p < 0.05 was used to calculate seizure-freedom and tolerability rates. RESULTS: At the end of the 24-month study period, 65.69% patients in the CBZ group continued to remain seizure free, 25.98% were drug failures, and 8.33% dropped out due to adverse events, with the corresponding numbers being 66.49%, 23.94%, and 9.57% in the LTG group and 72.44%, 12.99%, and 14.57% in the LEV group. Rash was the most common adverse event for CBZ (3.43%) and LTG (6.38%), and mood changes were the most commen adverse event for LEV (7.87%). Among the 3 groups (n = 646), AED tolerance rates and AED retention rates showed no significant difference (p = 0.08 and p = 0.23, respectively). Seizure-freedom rate difference among the 3 groups (n = 574) was significant (p = 0.003), and seizure-freedom rate for LEV was superior to CBZ (p = 0.001) and to LTG (p = 0.006). CONCLUSION: At the end of the 24-month study period, in a head-to-head comparison of single-source bioequivalent generic formulations, superior seizure-freedom rate and comparable tolerability and retention rates for LEV were observed when compared with CBZ and LTG.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Epilepsias Parciales / Anticonvulsivantes Tipo de estudio: Diagnostic_studies / Observational_studies Límite: Humans Idioma: En Revista: Perm J Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Epilepsias Parciales / Anticonvulsivantes Tipo de estudio: Diagnostic_studies / Observational_studies Límite: Humans Idioma: En Revista: Perm J Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos